iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $10.75 million. The enterprise value is $10.45 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 5.54 million shares outstanding. The number of shares has increased by 243.94% in one year.
| Current Share Class | 5.54M |
| Shares Outstanding | 5.54M |
| Shares Change (YoY) | +243.94% |
| Shares Change (QoQ) | +7.48% |
| Owned by Insiders (%) | 0.72% |
| Owned by Institutions (%) | 2.00% |
| Float | 5.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| Forward PS | n/a |
| PB Ratio | 9.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.23, with a Debt / Equity ratio of 0.46.
| Current Ratio | 0.23 |
| Quick Ratio | 0.19 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -49.57 |
Financial Efficiency
Return on equity (ROE) is -303.74% and return on invested capital (ROIC) is -195.74%.
| Return on Equity (ROE) | -303.74% |
| Return on Assets (ROA) | -76.70% |
| Return on Invested Capital (ROIC) | -195.74% |
| Return on Capital Employed (ROCE) | -1,275.46% |
| Revenue Per Employee | $246,170 |
| Profits Per Employee | -$424,679 |
| Employee Count | 24 |
| Asset Turnover | 0.66 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.66% in the last 52 weeks. The beta is 1.61, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -61.66% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 73.88 |
| Average Volume (20 Days) | 15,200,099 |
Short Selling Information
The latest short interest is 177,341, so 3.20% of the outstanding shares have been sold short.
| Short Interest | 177,341 |
| Short Previous Month | 231,409 |
| Short % of Shares Out | 3.20% |
| Short % of Float | 3.22% |
| Short Ratio (days to cover) | 0.38 |
Income Statement
In the last 12 months, iSpecimen had revenue of $5.91 million and -$10.19 million in losses. Loss per share was -$6.14.
| Revenue | 5.91M |
| Gross Profit | 1.93M |
| Operating Income | -11.01M |
| Pretax Income | -10.20M |
| Net Income | -10.19M |
| EBITDA | -10.75M |
| EBIT | -11.01M |
| Loss Per Share | -$6.14 |
Full Income StatementBalance Sheet
The company has $588,775 in cash and $287,885 in debt, giving a net cash position of $300,890 or $0.05 per share.
| Cash & Cash Equivalents | 588,775 |
| Total Debt | 287,885 |
| Net Cash | 300,890 |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 621,973 |
| Book Value Per Share | 0.21 |
| Working Capital | -4.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.94 million and capital expenditures -$47,864, giving a free cash flow of -$5.99 million.
| Operating Cash Flow | -5.94M |
| Capital Expenditures | -47,864 |
| Free Cash Flow | -5.99M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
Gross margin is 32.64%, with operating and profit margins of -186.28% and -172.51%.
| Gross Margin | 32.64% |
| Operating Margin | -186.28% |
| Pretax Margin | -172.51% |
| Profit Margin | -172.51% |
| EBITDA Margin | -181.89% |
| EBIT Margin | -186.28% |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -243.94% |
| Shareholder Yield | -243.94% |
| Earnings Yield | -94.84% |
| FCF Yield | -55.72% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 16, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iSpecimen has an Altman Z-Score of -22.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.82 |
| Piotroski F-Score | 1 |
